🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Lecia V. Sequist

Harvard University

ORCID: 0000-0002-8965-6991

Also affiliated with Cambridge Hospital, Massachusetts General Hospital, Global Cancer Institute, Center for Cancer Research, Mass General Brigham

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 14 papers. Top paper: “Blended palliative and survivorship care intervention (POISE) for patients with metastatic oncogene-driven non-small cell lung cancer: study protocol for a pilot randomised controlled trial”.

Blended palliative and survivorship care intervention (POISE) for patients with metastatic oncogene-driven non-small cell lung cancer: study protocol for a pilot randomised controlled trial

BMJ Open(2025)10.1136/bmjopen-2024-098075
N/A
0.104DataRank · unranked
1 citations

Roshni Sarathy, Dustin J. Rabideau, Jill Feldman, Leslie Cartagena, Heather Patel +7 more

Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E

JCO Precision Oncology(2024)10.1200/po.23.00454
N/A
0.104DataRank · unranked
1 citations

Zihe Song, Helena A. Yu, Lecia V. Sequist, Christine M. Lovly, Edith P. Mitchell +17 more

Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms

Cancer Cell(2021)10.1016/j.ccell.2021.09.003
N/A
0DataRank · unranked
263 citations

Zofia Piotrowska, Patricia J. Hare, Huidong Chen, Hillary E. Mulvey, Aislinn Mayfield +23 more

Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.01.010
N/A
0DataRank · unranked
42 citations

Zofia Piotrowska, Kevin Stirling, Stephen V. Liu, Mandeep K. Banwait, Kristen Cunanan +5 more

Phase II Study of Cabozantinib in Patients With Bone Metastasis

The Oncologist(2022)10.1093/oncolo/oyac083
N/A
0DataRank · unranked
9 citations

Gregory A. Coté, M. Dror Michaelson, Lori J. Wirth, Justin F. Gainor, Alona Muzikansky +6 more

Therapy-induced APOBEC3A drives evolution of persistent cancer cells

Nature(2023)10.1038/s41586-023-06303-1
N/A
0DataRank · unranked
148 citations

Ramin Sakhtemani, Ammal Abbasi, Naveed Nikpour, Marcello Stanzione, Sunwoo Oh +36 more

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis

JTO Clinical and Research Reports(2023)10.1016/j.jtocrr.2023.100534
N/A
0DataRank · unranked
13 citations

Lesli A. Kiedrowski, Rebecca S. Heist, W. Marston Linehan, Catherine B. Meador, Elizabeth Krueger +7 more

Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection

Cancer Discovery(2024)10.1158/2159-8290.cd-24-0519
N/A
0DataRank · unranked
77 citations

Peter B. Bach, Jacob Carey, Caitlin A. Schonewolf, Katalin Bognar, Manmeet S. Ahluwalia +33 more

Developmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumors

Nature Cancer(2024)10.1038/s43018-024-00840-y
N/A
0DataRank · unranked
21 citations

Ignaty Leshchiner, Christina L. Costantino, Martin Blohmer, Tilak Sundaresan, Justin Cha +21 more

Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB study

Lung Cancer(2024)10.1016/j.lungcan.2024.108003
N/A
0DataRank · unranked
8 citations

Alissa J. Cooper, Bruce E. Johnson, Justin F. Gainor, W. Marston Linehan, Lecia V. Sequist +6 more

GUK1 activation is a metabolic liability in lung cancer

Cell(2025)10.1016/j.cell.2025.01.024
N/A
0DataRank · unranked
16 citations

Kiran Kurmi, Yutong Dai, Ishita Dhiman, Shakchhi Joshi, Brandon M. Gassaway +21 more

ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9513
N/A
0DataRank · unranked
104 citations

Yating Wang, Lecia V. Sequist, Suresh S. Ramalingam, Zofia Piotrowska

Biomarker Testing and Patterns of Treatment in Patients with NSCLC: An International Association for The Study of Lung Cancer Analysis of American Society of Clinical Oncology CancerLinQ Discovery Data

JTO Clinical and Research Reports(2025)10.1016/j.jtocrr.2025.100816
N/A
0DataRank · unranked
0 citations

Gregory J. Joseph, Manali Rupji, Zhonglu Huang, Becky Bunn, Murry W. Wynes +7 more

Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2021.06.017
N/A
0DataRank · unranked
654 citations

Philip C. Mack, Giorgio V. Scagliotti, Charu Aggarwal, Maria E. Arcila, Fabrice Barlési +23 more